|Bid||155.68 x 800|
|Ask||267.86 x 1200|
|Day's Range||198.00 - 205.83|
|52 Week Range||118.18 - 426.56|
|Beta (5Y Monthly)||0.72|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 07, 2018 - Aug 13, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||315.21|
CAMBRIDGE, U.S. & BASEL, Switzerland & BEIJING, August 09, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing innovative and affordable oncology medicines to improve treatment outcomes and access for patients worldwide, today announced that the global Phase 3 RATIONALE 301 trial with tislelizumab met its primary endpoint of non-inferior Overall Survival (OS) versus sorafenib as a first-line treatment in adult patients with unresectable he
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, August 04, 2022--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company developing and commercializing innovative and affordable oncology medicines to improve treatment outcomes and access for far more patients worldwide, today reported financial results for the second quarter of 2022, recent business highlights, and anticipated upcoming milestones.
BeiGene (BGNE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.